StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Up 2.9 %

Shares of NYSE OGEN opened at $0.37 on Friday. The business has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.74. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74. The company has a market cap of $4.46 million, a P/E ratio of -0.05 and a beta of 0.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.